Skip to main content
SpringerLink
Log in

Endometrial Carcinoma and its Precursors

  • Chapter
  • First Online:
Hormonal Pathology of the Uterus

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1242))

Abstract

This chapter focuses on premalignant and malignant diseases of the endometrium (lining of the uterus). Endometrial carcinoma is the most common gynecologic cancer in the United States. Women have a 1 in 40 lifetime risk of being diagnosed with endometrial cancer, the fourth most common malignancy among women. An estimated 61,880 new diagnoses of uterine cancer and 12,160 deaths from the disease occurred in 2019 in the United States (American Cancer Society, Facts & Figures, https://www.cdc.gov/cancer/uterine/statistics/index.htm, 2019).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sponholtz T, Palmer J, Rosenberg L, Hatch E, Adams-Campbell L, Wise L. Reproductive factors and incidence of endometrial cancer in U.S. black women. Cancer Causes Control. 2017;28(6):579–88.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Setiawan V, Yang H, Pike M, McCann S, Yu H, Xiang Y, Wolk A. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607–18.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Deligdisch L, Marin T, Melana S, Mandel J, Holland JF, Pogo B. Human mammary tumor virus (HMTV) in endometrial carcinoma. Int J Gynecol Cancer. 2013;23:1423–8.

    Article  PubMed  Google Scholar 

  4. Bokhman J. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10.

    Article  CAS  PubMed  Google Scholar 

  5. Lewin S, Herzog T, Barrena MN, Deutsch I, Burke W, Sun X, Wright J. Comparative performance of the 2009 international federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol. 2010;116(5):1141–9.

    Article  PubMed  Google Scholar 

  6. Grice J, Ek M, Greer B, Koh W, Muntz H, Cain J, Tamimi H, Stelzer K, Figge D, Goff B. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol. 1998;69(1):69–73.

    Article  CAS  PubMed  Google Scholar 

  7. Damle R, Dravid N, Suryawanshi K, Gadre A, Bagale P, Ahire N. Clinicopathological Spectrum of endometrial changes in peri-menopausal and post-menopausal abnormal uterine bleeding: a 2 years study. J Clin Diagn Res. 2013;7(12):2774–6.

    PubMed  PubMed Central  Google Scholar 

  8. Kendall B, Ronnett B, Isacson C, Cho K, Hedrick L, Diener-West M, Kurman R. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol. 1998;22:1012.

    Article  CAS  PubMed  Google Scholar 

  9. Deligdisch L, Cohen CJ. Histologic correlates and virulence implication of endometrial carcinoma associated with adenomatous hyperplasia. Cancer. 1985;56:1452.

    Article  CAS  PubMed  Google Scholar 

  10. Fox H, Buckley C. The endometrial hyperplasias and their relationship to endometrial neoplasia. Histopathology. 1982;6:493.

    Article  CAS  PubMed  Google Scholar 

  11. Emons G, Beckmann M, Schmidt D, P. Mallmann and Uterus commission of the Gynecological Oncology Working Group (AGO). New WHO classification of endometrial hyperplasias. Geburtshilfe Frauenheilkd. 2015;75(2):135–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Gallos I, Ganesan R, Gupta J. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy. Obstet Gynecol. 2013;121(6):1165–71.

    Article  CAS  PubMed  Google Scholar 

  13. ACOG Practice Bulletin. Management of endometrial cancer. Obstet Gynecol. 2005;65.

    Google Scholar 

  14. Gal D, Edman C, Vellios F, Forney J. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia. Am J Obstet Gynecol. 1983;143(3):316–22.

    Article  Google Scholar 

  15. Cade T, Quinn M, Rome R, Neesham D. Progestogen treatment options for early endometrial cancer. BJOG. 2010;117(7):879–84.

    Article  CAS  PubMed  Google Scholar 

  16. Kurman R, Carcangiu M, Herrington C, R. E. Young and World Health Organization. WHO classification of tumours of the female reproductive organs. 2014. pp. 126–50.

    Google Scholar 

  17. Brinton L, Felix A, McMeekin D, Creasman W, Sherman M, Mutch D, Cohn D, Walker J, Moore R, Downs L, Soslow R, Zaino R. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013;129(2):277–84.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Creasman W, DeGeest K, DiSaia P, Zaino R. Significance of true surgical pathologic staging: a Gynecologic Oncology Group study. Am J Obstet Gynecol. 1999;181:31–4.

    Article  CAS  PubMed  Google Scholar 

  19. Deligdisch L, Kase NG, Bleiweiss IJ. Endometrial cancer in elderly women: a histologic and steroid receptor study. Gerontology. 2000a;46:17–21.

    Article  CAS  PubMed  Google Scholar 

  20. Vargas R, Rauh-Hain J, Clemmer J, Clark R, Goodman A, Growdon W, Schorge J, Del Carmen M, Horowitz N, Boruta DN. Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol. 2014;133(2):216–20.

    Article  PubMed  Google Scholar 

  21. Creasman W. Estrogen replacement therapy: is previously treated cancer a contraindication? Obstet Gynecol. 1991;77(2):308–12.

    Article  CAS  PubMed  Google Scholar 

  22. Creasman W, Henderson D, Hinshaw W, Clarke-Pearson D. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol. 1986;67(3):326–30.

    CAS  PubMed  Google Scholar 

  23. Dieudonne AS, Lambrechts D, Smeets D, Belmans A, Wildiers H, Paridaens R, Hyonil C, Timmerman D, Christiaens MR, Vergote I, Neven P. The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in post-menopausal women on tamoxifen. Ann Oncol. 2014;25:90–5.

    Article  PubMed  Google Scholar 

  24. Hrstka R, Podhorec J, Nenutil R, Sommerova L, Obacz J, Durech M, Faktor J, Bouchal P, Skoupilova H, Vojtesek B. Tamoxifen-dependent induction of AGR2 is associated with increased aggressiveness of endometrial Cancer cells. Cancer Investig. 2017;35:313–24.

    Article  CAS  Google Scholar 

  25. Magriples U, Naftolin F, Schwartz PE, Carcangiu M. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Clin Oncol. 1993;11:485–90.

    Article  CAS  PubMed  Google Scholar 

  26. Robinson DC, Bloss JD, Schiano MA. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol Oncol. 1995;59:186–90.

    Article  CAS  PubMed  Google Scholar 

  27. Deligdisch L, Kalir T, Cohen CJ, De Latour M, Le Bouedec G, Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Pathol. 2000b;78:181–6. Selected for Breast Diseases: A Yearbook Quarterly 2001, publ. Mosby Yearbook Inc.

    CAS  Google Scholar 

  28. Clark T, Barton P, Coomarasamy A, Gupta J, Khan K. Investigating postmenopausal bleeding for endometrial cancer: cost-effectiveness of initial diagnostic strategies. BJOG. 2006;113:502.

    Article  CAS  PubMed  Google Scholar 

  29. Dijkhuizen F, Mol B, Brölmann H, Heintz A. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000;89:1765.

    Article  CAS  PubMed  Google Scholar 

  30. Torres M, Weaver A, Kumar S, Uccella S, Famuyide A, Cliby W, Dowdy S, Gostout B, Mariani A. Risk factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol. 2012;120(5):998–1004.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Hwang J, Kim D, Bae H, Kim M, Jung Y, Yun B, Seong S, Shin E, Kim M. Combined oral medroxyprogesterone/Levonorgestrel-intrauterine system treatment for women with grade 2 stage IA endometrial Cancer. Int J Gynecol Cancer. 2017;27(4):738.

    Article  PubMed  Google Scholar 

  32. Park J, Kim D, Kim T, Kim J, Kim J, Kim Y, Kim Y, Bae D, Nam J. Hormonal therapy for women with stage IA endometrial cancer of all grades. Obstet Gynecol. 2013;122(1):7–14.

    Article  CAS  PubMed  Google Scholar 

  33. Creutzberg C, van Putten W, Koper P, Lybeert M, Jobsen J, Wárlám-Rodenhuis C, De Winter K, Lutgens L, van den Bergh A, van de Steen-Banasik E, Beerman H, van Lent M. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet. 2000;355(9213):1404–11.

    Article  CAS  PubMed  Google Scholar 

  34. Khoury-Collado F, Murray M, Hensley M, Sonoda Y, Alektiar K, Levine D, Leitao M, Chi D, Barakat R, Abu-Rustum N. Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to the regional lymph nodes. Gynecol Oncol. 2011;122(2):251–4.

    Article  CAS  PubMed  Google Scholar 

  35. Obermair A, et al. Endometrial cancer: accuracy of the finding of a well differentiated tumor at dilatation and curettage compared to the findings at subsequent hysterectomy. Int J Gynecol Cancer. 1999;9:383–6.

    Article  PubMed  Google Scholar 

  36. Deleon M, Ammakkanavar N, Matei D. Adjuvant therapy for endometrial cancer. J Gynecol Oncol. 2014;25(2):136–47.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Creutzberg C, van Putten W, Koper P, Lybeert M, Jobsen J, Wárlám-Rodenhuis C, De Winter K, Lutgens L, van den Bergh A, van der Steen-Banasik E, Beerman H, van Lent M, PORTEC Study Group. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003;89(2):201–9.

    Article  PubMed  Google Scholar 

  38. Gunderson C, Fader A, Carson K, Bristow R. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125(2):477.

    Article  CAS  PubMed  Google Scholar 

  39. American Cancer Society. American Cancer Society. Facts & Figures. 2019. https://www.cdc.gov/cancer/uterine/statistics/index.htm

Download references

Author information

Authors and Affiliations

  1. Robert Wood Johnson Barnabas Health Newark Beth Israel Medical Center, Newark, NJ, USA

    Pouya Javadian

  2. Nezhat Surgery for Gynecology/Oncology, New York, NY, USA

    Farr Nezhat

  3. Weill Cornell Medical College of Cornell University, New York, NY, USA

    Farr Nezhat

  4. Stony Brook University School of Medicine, Stony Brook, NY, USA

    Farr Nezhat

  5. Department of Minimally Invasive Gynecologic Surgery and Robotics, NYU Winthrop University Hospital, Mineola, NY, USA

    Farr Nezhat

Authors
  1. Pouya Javadian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Farr Nezhat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Farr Nezhat .

Editor information

Editors and Affiliations

  1. Professor Emeritus, Department of Pathology, Department of Obstetrics-Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Liane Deligdisch-Schor

  2. New York Medical College, Westchester Medical Center, Valhalla, NY, USA

    Angelica Mareş Miceli

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Javadian, P., Nezhat, F. (2020). Endometrial Carcinoma and its Precursors. In: Deligdisch-Schor, L., Mareş Miceli, A. (eds) Hormonal Pathology of the Uterus . Advances in Experimental Medicine and Biology, vol 1242. Springer, Cham. https://doi.org/10.1007/978-3-030-38474-6_4

Download citation

Publish with us

Policies and ethics

Search

Navigation